TRAIL-based tumour therapy has been the subject of many publications in recent years, and two approaches can be distinguished: treatment with recombinant human TRAIL (rhTRAIL), and therefore, activation of TRAIL receptors (DR4, DR5) or induction of TRAIL up-regulation28. This evidence concerns the gene TNFRSF10B and neoplasm.